Early-onset colorectal cancer: the decisions you may face
5 treatment settings, 4 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Screening and early diagnosis
Average-risk screening from age 45 (colonoscopy, faecal immunochemical test, stool DNA or blood test); earlier and more frequent colonoscopy for family history or a known syndrome; investigate rectal bleeding and iron deficiency promptly at any age.
Finding and removing polyps before they become cancer. Colonoscopy prevents cancer; stool and blood tests catch it early and get more people screened.
- Colonoscopy both detects and prevents by polypectomy
- Non-invasive options raise participation
The first FDA-approved blood test for colorectal cancer screening (2024), now optionally reporting other cancers too.
A home stool test done every three years that looks for cancer DNA and hidden blood; a positive result means you need a colonoscopy.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Blood and stool tests miss most precancerous polyps
- Colonoscopy capacity and access
- Early-onset cancers arise before screening age
- Between Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Shield and Cologuard, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Colon Cancer), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (screening and early diagnosis), which of the standard options do you recommend and why?Why: Guideline options include: Average-risk screening from age 45 (colonoscopy, faecal immunochemical test, stool DNA or blood test); earlier and more frequent colonoscopy for family history or a known syndrome; investigate rectal bleeding and iron deficiency promptly at any age.
- Am I a candidate for Shield, Cologuard, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.
Diagnosis and staging
Germline multigene testing for every patient; mismatch repair, RAS, BRAF and HER2 testing; fertility counselling before treatment.
A test of the DNA you were born with, to find inherited risk genes such as BRCA or Lynch syndrome.
- Actionable for patient and relatives
- Cheap
Histopathology means looking at cancer cells under a microscope, and immunohistochemistry stains them for specific proteins. Together they are still the foundation of every diagnosis.
- Cheap, fast, universal
- Companion diagnostic for most targeted drugs
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- VUS burden
- Uptake and counselling capacity
- Subjective scoring
- Single-site sampling misses heterogeneity
- Between Germline (hereditary) testing and Histopathology & immunohistochemistry, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Colon Cancer), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (diagnosis and staging), which of the standard options do you recommend and why?Why: Guideline options include: Germline multigene testing for every patient; mismatch repair, RAS, BRAF and HER2 testing; fertility counselling before treatment.
Add these to your appointment list, or take the full question set for this cancer.
Localised disease
As for colorectal and rectal cancer by stage: surgery, adjuvant FOLFOX or CAPOX for stage III, total neoadjuvant therapy or organ preservation for rectal tumours; no escalation on the basis of age alone.
FOLFOX is the workhorse chemotherapy combination for bowel cancer, used after surgery to cure and in advanced disease as the backbone that targeted drugs are added to.
CAPOX pairs the oral fluoropyrimidine capecitabine with intravenous oxaliplatin as a pill-based alternative to FOLFOX. For low-risk stage III colon cancer three months after surgery works as well as six and halves nerve damage; it is also standard in gastric cancer, with hand-foot syndrome as its price.
- High-risk locally advanced rectal cancer: short-course radiotherapy then chemotherapy before surgery (total neoadjuvant therapy) versus standard chemoradiation, surgery and optional adjuvant chemotherapy
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- 3-year disease-related treatment failure 23.7% vs 30.4%; pathological complete response 28% vs 14%.
Disease-related treatment failure at 3 years (%): Total neoadjuvant therapy 23.7 (n=462) vs Standard chemoradiation 30.4 (n=450)
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
- Between FOLFOX (5-FU, leucovorin, oxaliplatin) and CAPOX (capecitabine, oxaliplatin), which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in RAPIDO, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Colon Cancer), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (localised disease), which of the standard options do you recommend and why?Why: Guideline options include: As for colorectal and rectal cancer by stage: surgery, adjuvant FOLFOX or CAPOX for stage III, total neoadjuvant therapy or organ preservation for rectal tumours; no escalation on the basis of age alone.
- Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), CAPOX (capecitabine, oxaliplatin), and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of RAPIDO apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Metastatic disease
Genotype-directed therapy as for all metastatic colorectal cancer: checkpoint blockade if mismatch-repair deficient, encorafenib-cetuximab for BRAF V600E, HER2 or KRAS G12C combinations, otherwise chemotherapy with bevacizumab or an anti-EGFR antibody by sidedness.
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
Encorafenib is a BRAF inhibitor that, with cetuximab and chemotherapy, became first-line standard for BRAF-mutant colorectal cancer in 2026.
A HER2-selective pill that works in the brain, for HER2-positive breast cancer with brain metastases.
Sotorasib (Lumakras) was the first drug to hit KRAS, approved in 2021 after four decades of failure.
Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.
Cetuximab is a chimeric antibody that blocks the EGFR growth receptor. It is used with FOLFIRI or FOLFOX in RAS wild-type, left-sided bowel cancer, with encorafenib in BRAF V600E disease, with KRAS G12C inhibitors, and with radiation or chemotherapy in head and neck cancer; RAS-mutant tumours gain nothing and may be harmed, so RAS testing comes first.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypothyroidism (immune-mediated) · Pooled monotherapy data, >2,800 patients | 8% | - |
| Pneumonitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 3.4% | - |
| Colitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 1.7% | - |
| Hepatitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 0.7% | - |
- No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.
- Reduce to 200 mg twice daily in severe impairment.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hepatotoxicity · CodeBreaK 100 | 25% | 12% |
| Interstitial lung disease · CodeBreaK 100 | 2.2% | 1.1% |
| Diarrhoea · CodeBreaK 100 | 42% | - |
| Musculoskeletal pain · CodeBreaK 100 | 35% | - |
- No adjustment for mild impairment; hepatotoxicity is common and worse after recent immunotherapy.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Between Pembrolizumab, Encorafenib, Tucatinib and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- Which side effects of Pembrolizumab or Sotorasib are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Colon Cancer), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (metastatic disease), which of the standard options do you recommend and why?Why: Guideline options include: Genotype-directed therapy as for all metastatic colorectal cancer: checkpoint blockade if mismatch-repair deficient, encorafenib-cetuximab for BRAF V600E, HER2 or KRAS G12C combinations, otherwise chemotherapy with bevacizumab or an anti-EGFR antibody by sidedness.
- Am I a candidate for Pembrolizumab, Encorafenib, Tucatinib or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.
Survivorship
Structured exercise (CHALLENGE), long-term neuropathy and bowel function care, fertility and sexual health follow-up, financial and employment support.
Structured exercise during and after treatment, which the CHALLENGE trial showed improves survival in colon cancer.
- Cheap, safe, patient-controlled
- Resected stage III or high-risk stage II colon cancer after adjuvant chemotherapy: 3-year structured exercise programme vs health-education materials
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- DFS HR 0.72; OS HR 0.63; 8-year OS 90.3% vs 83.2%.
Disease-free survival at 5 years (%): Structured exercise 80.3 (n=445) vs Health education 73.9 (n=444) · HR 0.72 · source
- Delivery and adherence at scale
- Is Exercise & lifestyle oncology the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?Why: A single standard does not mean a single choice; timing and trials are decisions too.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in CHALLENGE (CCTG CO.21), and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Colon Cancer), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (survivorship), which of the standard options do you recommend and why?Why: Guideline options include: Structured exercise (CHALLENGE), long-term neuropathy and bowel function care, fertility and sexual health follow-up, financial and employment support.
- How do the results of CHALLENGE (CCTG CO.21) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.